NCT04638660 - Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) in Subjects With Dim Light Vision Disturbances | Biotech Hunter

Enrollment

144

Participants

Timeline

Start Date

December 30, 2020

Primary Completion Date

May 19, 2022

Study Completion Date

May 19, 2022

Conditions

Dim Light Vision Disturbances

Interventions

DRUG

Phentolamine Ophthalmic Solution 0.75%

0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist

DRUG

Phentolamine Ophthalmic Solution Vehicle (Placebo)

Topical sterile ophthalmic solution

Trial Locations (17)

27262

Clinical Site 22, High Point

Clinical Site 9, High Point

27909

Clinical Site 4, Elizabeth City

32204

Clinical Site 3, Jacksonville

32256

Clinical Site 18, Jacksonville

38119

Clinical Site 11, Memphis

41008

Clinical Site 14, Louisville

41017

Clinical Site 20, Edgewood

57108

Clinical Test 15, Warwick

58103

Clinical Site 2, Fargo

66762

Clinical Site 13, Pittsburg

78240

Clinical Site 5, San Antonio

84403

Clinical Site 19, Ogden

92663

Clinical Site 6, Newport Beach

94954

Clinical Site 1, Petaluma

07650

Clinical Site 10, Palisades Park

08534

Clinical Site 8, Pennington